Deadly allies: The fatal interplay between platelets and metastasizing cancer cells

Blood

Volumn 115, Issue 17, 2010, Pages 3427-3436

  Erpenbeck, Luise ^a   Schön, Michael P ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; APT 102; APYRASE; DALTEPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN; GLYCOPROTEIN IB; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN IX; GLYCOPROTEIN V; GLYCOPROTEIN VI; INTEGRIN; NADROPARIN; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; PURINERGIC P2Y RECEPTOR; THROMBIN RECEPTOR; TINZAPARIN; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 2; WARFARIN; [[[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETYL]AMINO] N [(3 METHYLPHENYL)SULFONYL]ALANINE;

ADVANCED CANCER; BONE METASTASIS; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CELL FUNCTION; CELL INTERACTION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE COMPARISON; DRUG TARGETING; ESOPHAGUS CANCER; GYNECOLOGIC CANCER; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; LUNG METASTASIS; MELANOMA; METASTASIS; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; STOMACH CANCER; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; UROGENITAL TRACT CANCER; UTERUS CANCER;

EID: 77951708287     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-247296     Document Type: Review

References (106)

1. Trousseau A. Phlegmasia alba dolens. In: Clinique Medicale de l'Hotel-Dieu de Paris, 2nd ed. Paris, France: JB Baillière & Fils; 1865:654-712.
2. Sørensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998; 338(17):1169-1173. (Pubitemid 28180744)
3. Tranum BL, Haut A. Thrombocytosis: platelet kinetics in neoplasia. J Lab Clin Med. 1974;84(5): 615-619.
4. Scholz HS, Petru E, Gucer F, Haas J, Tamussino K, Winter R. Preoperative thrombocytosis is an independent prognostic factor in stage III and IV endometrial cancer. Anticancer Res. 2000; 20(5C):3983-3985. (Pubitemid 32002309)
5. Ayhan A, Bozdag G, Taskiran C, Gultekin M, Yuce K, Kucukali T. The value of preoperative platelet count in the prediction of cervical involvement and poor prognostic variables in patients with endometrial carcinoma. Gynecol Oncol. 2006;103(3): 902-905. (Pubitemid 44830067)
6. Hernandez E, Lavine M, Dunton CJ, Gracely E, Parker J. Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer. 1992;69(12):2975-2977.
7. Zeimet AG, Marth C, Muller-Holzner E, Daxenbichler G, Dapunt O. Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1994;170(2):549-554. (Pubitemid 24089013)
8. Ikeda M, Furukawa H, Imamura H, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002; 9(3):287-291. (Pubitemid 34298634)
9. Shimada H, Oohira G, Okazumi S, et al. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg. 2004;198(5):737-741. (Pubitemid 38542902)
10. Estrov Z, Talpaz M, Mavligit G, et al. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med. 1995;98(6):551-558.
11. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004;4(6):448-456.
12. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest. 1988;81(4):1012-1019.
13. Karpatkin S, Ambrogio C, Pearlstein E. The role of tumor-induced platelet aggregation, platelet adhesion and adhesive proteins in tumor metastasis. Prog Clin Biol Res. 1988;283:585-606.
14. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A. 1968;61(1):46-52.
15. Gasic GJ. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev. 1984;3(2):99-114.
16. Erpenbeck L, Nieswandt B, Schön M, Pozgajova M, Schön MP. Inhibition of platelet GPIbalpha and promotion of melanoma metastasis. J Invest Dermatol. 2010;130(2):576-586.
17. Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105(1): 178-185.
18. Amirkhosravi A, Mousa SA, Amaya M, et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost. 2003;90(3):549-554. (Pubitemid 37138780)
19. Im JH, Fu W, Wang H, et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 2004;64(23):8613-8619. (Pubitemid 39552074)
20. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999; 59(6):1295-1300. (Pubitemid 29136261)
21. Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009;69(19):7775-7783.
22. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001;102(6):V215-V224. (Pubitemid 32539212)
23. Kepner N, Lipton A. A mitogenic factor for transformed fibroblasts from human platelets. Cancer Res. 1981;41(2):430-432. (Pubitemid 11179375)
24. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombininduced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997;94(2):663-668. (Pubitemid 27053690)
25. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006;10(5):355-362. (Pubitemid 44693468)
26. Ho-Tin-Noé B, Goerge T, Cifuni SM, Duerschmied D, Wagner DD. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res. 2008; 68(16):6851-6858.
27. Ho-Tin-Noé B, Goerge T, Wagner DD. Platelets: guardians of tumor vasculature. Cancer Res. 2009;69(14):5623-5626.
28. Terraube V, Pendu R, Baruch D, et al. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost. 2006;4(3):519-526.
29. Simon DI, Chen Z, Xu H, et al. Platelet glycoprotein Ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med. 2000; 192(2):193-204. (Pubitemid 30470302)
30. Romo GM, Dong JF, Schade AJ, et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med. 1999;190(6): 803-814.
31. Andrews RK, Gardiner EE, Shen Y, Whisstock JC, Berndt MC. Glycoprotein Ib-IX-V. Int J Biochem Cell Biol. 2003;35(8):1170-1174.
32. Berndt MC, Shen Y, Dopheide SM, Gardiner EE, Andrews RK. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost. 2001; 86(1):178-188. (Pubitemid 32663951)
33. Canobbio I, Balduini C, Torti M. Signalling through the platelet glycoprotein Ib-V-IX complex. Cell Signal. 2004;16(12):1329-1344. (Pubitemid 39277499)
34. Oleksowicz L, Mrowiec Z, Schwartz E, Khorshidi M, Dutcher JP, Puszkin E. Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thromb Res. 1995;79(3):261-274.
35. Alonso-Escolano D, Strongin AY, Chung AW, Deryugina EI, Radomski MW. Membrane type-1 matrix metalloproteinase stimulates tumour cellinduced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol. 2004;141(2):241-252. (Pubitemid 38250894)
36. Bergmeier W, Rackebrandt K, Schroder W, Zirngibl H, Nieswandt B. Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. Blood. 2000;95(3):886-893. (Pubitemid 30062710)
37. Bastida E, Almirall L, Ordinas A. Tumor-cellinduced platelet aggregation is a glycoproteindependent and lipoxygenase-associated process. Int J Cancer. 1987;39(6):760-763. (Pubitemid 17087878)
38. Grossi IM, Fitzgerald LA, Kendall A, Taylor JD, Sloane BF, Honn KV. Inhibition of human tumor cell induced platelet aggregation by antibodies to platelet glycoproteins Ib and IIb/IIIa. Proc Soc Exp Biol Med. 1987;186(3):378-383. (Pubitemid 18055368)
39. Jain S, Zuka M, Liu J, et al. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci U S A. 2007;104(21):9024-9028. (Pubitemid 47175430)
40. Kato K, Martinez C, Russell S, et al. Genetic deletion of mouse platelet glycoprotein Ibbeta produces a Bernard-Soulier phenotype with increased alpha-granule size. Blood. 2004;104(8): 2339-2344. (Pubitemid 39331831)
41. Kanaji T, Russell S, Ware J. Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome. Blood. 2002; 100(6):2102-2107. (Pubitemid 35001244)
42. Poujol C, Ware J, Nieswandt B, Nurden AT, Nurden P. Absence of GPIbalpha is responsible for aberrant membrane development during megakaryocyte maturation: ultrastructural study using a transgenic model. Exp Hematol. 2002; 30(4):352-360. (Pubitemid 34286441)
43. Ludwig RJ, Boehme B, Podda M, et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 2004;64(8):2743-2750. (Pubitemid 38500611)
44. Terraube V, Marx I, Denis CV. Role of von Willebrand factor in tumor metastasis. Thromb Res. 2007;120(suppl 2):S64-S70. (Pubitemid 350101773)
45. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 1998;94(5):657-666. (Pubitemid 28427584)
46. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003; 102(2):449-461. (Pubitemid 36841960)
47. Farndale RW, Sixma JJ, Barnes MJ, de Groot PG. The role of collagen in thrombosis and hemostasis. J Thromb Haemost. 2004;2(4):561-573.
48. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673-687.
49. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood. 2004;104(6):1606-1615. (Pubitemid 39202265)
50. Nieswandt B, Brakebusch C, Bergmeier W, et al. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J. 2001;20(9):2120-2130. (Pubitemid 32410582)
51. Lockyer S, Okuyama K, Begum S, et al. GPVIdeficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism. Thromb Res. 2006;118(3): 371-380. (Pubitemid 44067198)
52. Hall CL, Dubyk CW, Riesenberger TA, Shein D, Keller ET, van Golen KL. Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia. 2008;10(8):797-803.
53. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood. 1998;91(8): 2645-2657.
54. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res. 2007; 100(12):1673-1685.
55. Trikha M, Zhou Z, Timar J, et al. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. 2002;62(10):2824-2833. (Pubitemid 34525767)
56. Amirkhosravi A, Amaya M, Siddiqui F, Biggerstaff JP, Meyer TV, Francis JL. Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis. Platelets. 1999; 10(5):285-292. (Pubitemid 29490854)
57. Engebraaten O, Trikha M, Juell S, Garman-Vik S, Fodstad O. Inhibition of in vive tumour growth by the blocking of host alpha (v) beta3 and alphaII(b) beta3 integrins. Anticancer Res. 2009;29(1):131-137.
58. Trikha M, Raso E, Cai Y, et al. Role of alphaII(b-)beta3 integrin in prostate cancer metastasis. Prostate. 1998;35(3):185-192. (Pubitemid 28211292)
59. Chen YQ, Trikha M, Gao X, et al. Ectopic expression of platelet integrin alphaIIb beta3 in tumor cells from various species and histological origin. Int J Cancer. 1997;72(4):642-648. (Pubitemid 27356167)
60. Fabre JE, Nguyen M, Latour A, et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med. 1999;5(10):1199-1202. (Pubitemid 29474427)
61. Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nucleotide receptor signaling in platelets. J Thromb Haemost. 2006;4(11):2317-2326.
62. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113(3):340-345. (Pubitemid 38544175)
63. Boukerche H, Benchaibi M, Berthier-Vergnes O, et al. Two human melanoma cell-line variants with enhanced in vivo tumor growth and metastatic capacity do not express the beta 3 integrin subunit. Eur J Biochem. 1994;220(2):485-491. (Pubitemid 24092815)
64. Uluçkan O, Eagleton MC, Floyd DH, et al. APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J Cell Biochem. 2008;104(4):1311-1323. (Pubitemid 351961703)
65. Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev. 1999;79(1):181-213. (Pubitemid 29056952)
66. Yang J, Furie BC, Furie B. The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte- platelet interaction. Thromb Haemost. 1999;81(1):1-7. (Pubitemid 29041639)
67. Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 1992;359(6398):848-851.
68. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003;197(11):1585- 1598. (Pubitemid 36682554)
69. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A. 2002; 99(4):2193-2198. (Pubitemid 34169037)
70. Mannori G, Crottet P, Cecconi O, et al. Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer Res. 1995;55(19):4425-4431.
71. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, Pselectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A. 2001;98(6):3352-3357. (Pubitemid 32220849)
72. Nakamori S, Kameyama M, Imaoka S, et al. Increased expression of sialyl Lewis x antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res. 1993;53(15): 3632-3637. (Pubitemid 23229648)
73. Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A. 1998;95(16):9325-9330. (Pubitemid 28506230)
74. Stevenson JL, Varki A, Borsig L. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res. 2007; 120(suppl 2):S107-S111. (Pubitemid 350101778)
75. Varki A. Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature. 2007;446(7139):1023-1029. (Pubitemid 46676064)
76. Davey MG, Lüscher EF. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature. 1967;216(5118):857-858.
77. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975;72(8):2994-2998.
78. Henn V, Slupsky JR, Gräfe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391(6667): 591-594. (Pubitemid 28157601)
79. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64(6):1057-1068.
80. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103(6): 879-887. (Pubitemid 29152634)
81. Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature. 1998;394(6694):690-694. (Pubitemid 28389797)
82. Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest. 1991; 87(1):229-236.
83. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A. 1995;92(18):8205-8209.
84. Fischer EG, Ruf W, Mueller BM. Tissue factorinitiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res. 1995;55(8):1629-1632.
85. Nierodzik ML, Chen K, Takeshita K, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood. 1998; 92(10):3694-3700. (Pubitemid 28525196)
86. Wojtukiewicz MZ, Tang DG, Nelson KK, Walz DA, Diglio CA, Honn KV. Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. Thromb Res. 1992;68(3):233-245.
87. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol. 1996;149(1):293-305. (Pubitemid 26231000)
88. Nierodzik ML, Bain RM, Liu LX, Shivji M, Takeshita K, Karpatkin S. Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumor tyrosine phosphorylation. Br J Haematol. 1996;92(2):452-457. (Pubitemid 26042943)
89. Klepfish A, Greco MA, Karpatkin S. Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. Int J Cancer. 1993;53(6):978-982. (Pubitemid 23119547)
90. Dardik R, Savion N, Kaufmann Y, Varon D. Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: role of platelet glycoproteins P-selectin and GPIIb-IIIA. Br J Cancer. 1998;77(12):2069-2075. (Pubitemid 28263924)
91. Helland IB, Klementsen B, Jorgensen L. Addition of both platelets and thrombin in combination accelerates tumor cells to adhere to endothelial cells in vitro. In Vitro Cell Dev Biol Anim. 1997; 33(3):182-186. (Pubitemid 27175042)
92. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, proteaseactivated receptors, and fibrinogen in hematogenous metastasis. Blood. 2004;104(2):397-401. (Pubitemid 38900020)
93. Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer: "Petites Cellules" Group. Cancer. 1994;74(1):38-45.
94. Ornstein DL, Zacharski LR. The use of heparin for treating human malignancies. Haemostasis. 1999;29(suppl 1):48-60.
95. Gerotziafas GT, Papageorgiou C, Hatmi M, Samama MM, Elalamy I. Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb. 2008; 36(3):204-211.
96. Zielinski CC, Hejna M. Warfarin for cancer prevention. N Engl J Med. 2000;342(26):1991-1993.
97. Zacharski LR, Lee AY. Heparin as an anticancer therapeutic. Expert Opin Investig Drugs. 2008; 17(7):1029-1037.
98. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins: correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res. 2005; 11(19):7003-7011. (Pubitemid 41428760)
99. Ludwig RJ, Alban S, Bistrian R, et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost. 2006;95(3):535-540.
100. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23(10):2123-2129. (Pubitemid 46218703)
101. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004; 2(8):1266-1271. (Pubitemid 40186120)
102. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22(10):1944-1948. (Pubitemid 41095187)
103. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23(10):2130-2135. (Pubitemid 46218704)
104. Sideras K, Schaefer PL, Okuno SH, et al. Lowmolecular- weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006;81(6):758-767. (Pubitemid 43839491)
105. Griffiths GO, Burns S, Noble SI, Macbeth FR, Cohen D, Maughan TS. FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer. 2009;9:355.
106. Kneuer C, Ehrhardt C, Radomski MW, Bakowsky U. Selectins: potential pharmacological targets? Drug Discov Today. 2006;11(21):1034-1040.